1. Opening Hook
Just when Big Pharma thought India’s insulin market couldn’t get more crowded, Sanofi pulled out a fresh AI-powered syringe. While Novo Nordisk vacates, Sanofi’s Toujeo and Soliqua slide into the doctor’s drawer with confidence. CFO Rachid Ayari swears this is transformation, not “just another cost optimization deck.”
As the Quran says, “Indeed, Allah will not change the condition of a people until they change what is in themselves.” Sanofi seems to have taken that literally—digitally empowering everyone, even their spreadsheets.
Keep reading—the insulin gets thicker, the AI gets smarter, and the exports get… interesting.
2. At a Glance
- Revenue up ~5% – CFO calls it “accelerated growth,” auditors call it arithmetic.
- OPEX down 30% – HR finally got that “AI assistant” who doesn’t demand Diwali bonus.
- Margins improved to 29% – Insulin burns fat, margins build muscle.
- Exports down ~12–13% – Goa site got promoted, Ankleshwar went on sabbatical.
- Dividend: ₹75/share – Because profits may be steady, but generosity is insulin-resistant.
3. Management’s Key Commentary
Eric Mansion: “We’ve modernized our business model to strengthen insulin leadership.”
(Translation: The diet plan was too long; we’re finally seeing abs.) 😏
Rachid Ayari: “Exports fell due to Ankleshwar site divestment, but no impact on profit.”
(Translation: Losing weight in revenue, not in waistline.)
Deepak Arora: “We’re positioning for sustainable growth and AI-led excellence.”
(Translation: PowerPoint now writes itself.)
Suresh Babu: “Soliqua offers a more convenient treatment backed by clinical evidence.”
(Translation: It’s the same insulin, just dressed like an iPhone.)
Eric Mansion: “We’re digitally empowering teams with AI tools.”
(Translation: Humans still present,
